TGF-β-Upregulated Lnc-Nr6a1 Acts as a Reservoir of miR-181 and Mediates Assembly of a Glycolytic Complex

Citation: Polo-Generelo, S.; Torres, B.; Guerrero-Martínez, J.A.; Camafeita, E.; Vázquez, J.; Reyes, J.C.; Pintor-Toro, J.A. TGF-β-Upregulated Lnc-Nr6a1 Acts as a Reservoir of miR-181 and Mediates Assembly of a Glycolytic Complex. Non-Coding RNA 2022,8, 62. https://doi.org/ 10.3390/ncrna8050062 Academic Editor: George A Calin Received: 5 August 2022 Accepted: 10 September 2022 Published: 15 September 2022 Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). non-coding RNA Article TGF-β-Upregulated Lnc-Nr6a1 Acts as a Reservoir of miR-181 and Mediates Assembly of a Glycolytic Complex Salvador Polo-Generelo 1, Belén Torres 1, JoséA. Guerrero-Martínez 1, Emilio Camafeita 2,3 , Jesús Vázquez 2,3 , JoséC. Reyes 1and JoséA. Pintor-Toro 1,* 1Department of Cell Signalling, Centro Andaluz de Biología Molecular y Medicina Regenerativa (CABIMER-CSIC), 41092 Sevilla, Spain 2Cardiovascular Proteomics, Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain 3CIBER de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain *Correspondence: [email protected]; Tel.: +34-954467995 Abstract: Long non-coding RNAs (lncRNAs) have emerged as key regulators in a wide range of biological processes. Here, we identified a mouse miRNA-host gene lncRNA (Lnc-Nr6a1) upregulated early during epithelial-to-mesenchymal transition (EMT). We show that when lncRNA is processed, it gives rise to two abundant polyadenylated isoforms, lnc-Nr6a1-1 and lnc-Nr6a1-2, and a longer non-polyadenylated microprocessor-driven lnc-pri-miRNA containing clustered pre-miR-181a2 and pre-miR-181b2 hairpins. Ectopic expression of the lnc-Nr6a1-1 or lnc-Nr6a1-2 isoform enhanced cell migration and the invasive capacity of the cells, whereas the expression of the isoforms and miR-181a2 and miR-181b2 conferred anoikis resistance. Lnc-Nr6a1 gene deletion resulted in cells with lower adhesion capacity and reduced glycolytic metabolism, which are restored by lnc-Nr6a1-1 isoform expression. We performed identification of direct RNA interacting proteins (iDRIP) to identify proteins interacting directly with the lnc-Nr6a1-1 isoform. We defined a network of interacting proteins, including glycolytic enzymes, desmosome proteins and chaperone proteins; and we demonstrated that the lnc-Nr6a1-1 isoform directly binds and acts as a scaffold molecule for the assembly of ENO1, ALDOA, GAPDH, and PKM glycolytic enzymes, along with LDHA, supporting substrate channeling for efficient glycolysis. Our results unveil a role of Lnc-Nr6a1 as a multifunctional lncRNA acting as a backbone for multiprotein complex formation and primary microRNAs. Keywords: lncRNA; miRNA-host genes; microprocessor; cell adhesion; anoikis; glycolytic scaffold 1. Introduction EMT is a reversible transdifferentiation process in which epithelial cells lose their characteristics and instead acquire attributes of mesenchymal cells. During EMT, cell-cell junctions are disrupted, the actin cytoskeleton is extensively reorganized and the cells acquire increased migratory and invasive characteristics [ 1 , 2 ]. EMT is essential in several physiological and pathological processes, including embryonic development, wound healing, organ fibrosis and cancer progression [ 3 ]. The EMT process entails substantial changes in gene expression. Beyond the well-stablished transcriptional reprogramming during EMT, posttranscriptional mechanisms, such as regulation by alternative pre-mRNA splicing and non-coding RNA, have an important role and provide additional layers of complexity in gene regulation [4–6]. Long non-coding RNAs (lncRNAs) are defined as RNA transcripts longer than 200 nucleotides, with no apparent protein-coding potential. More than 16,000 lncRNA genes have been identified in the human genome, on the basis of GENCODE annotations (Human GENCODE Release, v27), but only a small percentage of these have been functionally characterized. Notably, their expression is strikingly cell-type or tissue-restricted [ 7 ]. Studies on lncRNAs have demonstrated that they serve important roles in gene regulation as Non-Coding RNA 2022,8, 62. https://doi.org/10.3390/ncrna8050062 https://www.mdpi.com/journal/ncrna Non-Coding RNA 2022,8, 62 2 of 27 molecular scaffold or guides modulating nucleic acid-nucleic acid, nucleic acid-protein or protein-protein interactions, or competing endogenous RNAs that bind proteins or microRNAs (miRNAs); and as enhancers of gene expression when transcribed within enhancer regions or their neighboring loci [ 8 , 9 ]. Some lncRNAs harbor miRNAs within their exonic or intronic sequences, and hence are processed to produce miRNAs that promote mRNA decay or repress target mRNAs. For example, lncRNA-H19 exon1 encodes miR-675 miRNA that suppresses the translation of the Igf1r gene, inhibiting cell proliferation [ 10 ]; miR100 and miR-125b generated from the lncRNA MiR100HG mediate cetuximab resistance via Wnt/b-catenin signaling [ 11 ]; PVT1 lncRNA, which is processed from the MIRHG harboring the miR-1204, miR-1205, miR-1206, miR-1207-5p, miR-1207-3p and miR-1208 cluster positively regulates c-Myc expression and activity [ 12 ]. A major question that needs to be answered is whether these lncRNAs are merely serving as primary miRNA units for producing miRNAs, or if they might also generate mature lncRNAs that have independent roles. In the present work, we studied a TGFβ -responsive lncRNA, we named Lnc-Nr6a1, expressed early during EMT. Two polyadenylated isoforms, lnc-Nr6a1-1 and lnc-Nr6a1-2, and a longer non-polyadenylated isoform were generated from Lnc-Nr6a1 genomic loci. The non-polyadenylated isoform contains pri-miR181a2 and pri-miR181b2 sequences, which are Dicer processed generating mature miR-181a2 and miR-181b2. We showed that migration and invasiveness of the cell increase by ectopic expression of the polyadenylated isoforms, whereas anoikis resistance increases by expression of the non-polyadenylated isoform, proving that transcripts generated from Lnc-Nr6a1 genomic loci perform independent functions. Lnc-Nr6a1 gene depletion causes defects in cell adhesion and metabolic changes that are reverted by exogenous expression of the polyadenylated lnc-Nr6a1-1 isoform. We demonstrated that this lncRNA isoform interacts directly with the proteins of several functional groups and serves as molecular scaffold enabling the formation of a multienzyme complex between ENO1, ALDOA, GAPDH, and PKM glycolytic enzymes, along with LDHA, and contributing to a higher level of glycolysis. 2. Results 2.1. Upregulation of Lnc-Nr6a1 and Embedded miR-181a2 and miR-181b2 during EMT To systematically identify lncRNAs involved early in the EMT process, transcriptional profiling was performed in untreated NMuMG mammary epithelial cells and NMuMG cells treated with TGFβ for 2 h using microarrays that covered 31,423 annotated lncRNAs and also 25,376 protein-coding transcripts [ 5 ]. Among PCR-confirmed candidates, Nr6a1os was one of the most significantly induced non-coding RNAs. This gene maps on chromosome 2 and is transcribed from the third intron of the Nr6a1 gene in the opposite sense. Two isoforms of 650 bp and 645 bp, here named lnc-Nr6a1-1 and lnc-Nr6a1-2, respectively, were induced early after TGFβ treatment. The isoform lnc-Nr6a1-1 is composed of three exons separated by introns of 16,600 and 13,806 bp, and lnc-Nr6a1-2 of two exons and an intron of 14,699 bp. MiR-181a2 and miR-181b2 genes are located at 314 and 1410 bp downstream, respectively, of the 3 0 end of lnc-Nr6a1-1 (Figure 1A). Exon2and miR-181a2/b2-specific probes showed that an unprocessed lnc-pri-miR-181a2/b2 transcript was generated containing spliced exon1, exon2 and exon3 and an unprocessed fragment with embedded miR-181a2 and miR-181b2 genes (Figure 1A–C). Quantitative reversetranscription PCR (RT-qPCR) of poly(A + )- and poly(A − )-selected RNA showed that the lnc-Nr6a1-1 isoform was found in both RNA populations, in contrast to the lnc-Nr6a1-2 isoform that was found only in the poly(A + ) RNA population. We validated the enrichment using primers specific for a polyadenylated mRNA (Hprt) and non-polyadenylated RNA (U6) (Figure 1D). To map lnc-pri-miR-181a2/b2 3 0 ends at nucleotide resolution, we developed both a poly(A + ) tail–dependent and a poly(A + ) tail–independent 3 0 rapid amplification of cDNA ends (3 0 RACE) technique. Two poly(A + )-dependent polyadenylation sites were mapped, one of them located after the second exon of the lnc-Nr6a1-2 isoform, according to the annotation ENSMUST00000129089.2 from GENECODE, with a Non-Coding RNA 2022,8, 62 3 of 27 canonical AATAA polyadenylation signal occurring 35 nt upstream from the poly(A) tail, and the other one located after the third exon of lnc-Nr6a1-1, 49 nucleotides longer than the ENSMUST00000151229.2 transcript annotation, with a noncanonical AATTAAA polyadenylation signal occurring 19 nt upstream from the poly(A) tail (Figure S1A). Four poly(A + ) tail-independent polyadenylation sites were mapped, corresponding to the sites of Drosha cleavage on the 5 0 arm of the pre-miR-181a2 and pre-miR-181b2, respectively; and the site of Drosha cleavage on the 3 0 arm of the pre-miR-181a2 and pre-miR-181b2, respectively (Figures S1A and S2A,B). These results indicate that the lnc-Nr6a1-1 isoform is transcribed as a polyadenylated RNA and also as a precursor non-polyadenylated RNA, which would be processed by the Microprocessor complex providing pre-miR-181a2 and pre-miR-181b2 molecules and a lncRNA molecule that would be degraded since it is not detected using specific primers. We determined by 5 0 rapid amplification of cDNA ends (5 0 RACE) that lncNr6a1-1 is a transcript 75 nucleotides longer at the 5 0 end than the ENSMUST00000151229.2 transcript annotation (Figures S1B and 2C,D). Lnc-Nr6a1 is located at the third intron of the Nr6a1 gene, and its transcription could play a cis-regulatory role in the expression of this gene. However, Nr6a1 expression, unlike lnc-Nr6a1 isoforms and miR-181a2/b2, is hardly affected by treatment with TGFβ (Figure 1E–G). Likewise, Nr6a1 transcript levels were low in most tissues and organs analyzed except in testis, while expression profiles of lnc-Nr6a1 isoforms in multiple adult tissues showed that they were expressed notably in skeletal muscle, and differed markedly in other tissues or organs; therefore, lnc-Nr6a1-1 was expressed in the eyes while lnc-Nr6a1-2 was expressed in bone marrow and the thymus, suggesting that they could regulate different biological processes (Figure 1H,I). Together these data demonstrate that the expression of Lnc-Nr6a1 and Nr6a1 genes are not matched. Sequence analysis using ORF Finder (National Centre for Biotechnology Information) predicted open reading frames smaller than 43 amino acids without a valid Kozack sequence. In addition, a low-coding potential score ( − 0.83 and − 0.86) and a low-coding probability (0.028 and 0.028) returned by the Coding Potential Calculator software [ 13 ] and Coding-Potential Assessment Tool [ 14 ], respectively, confirmed a negligible protein coding potential for lnc-Nr6a1-1 and lnc-Nr6a1-2, respectively (Figure S3). A human Lnc-NR6A1 orthologue transcript produced by the syntenic locus in chromosome 9 displays an overall 60% and 68% sequence identity with lnc-Nr6a1-1 and lnc-Nr6a1-2, respectively. It is composed of 2 exons of 330 and 387 bp and an intron of 40,220 bp that harbors mir-181a2 and mir-181b2 genes. In a similar way to the murine counterpart, expression of the human transcript was induced in MCF-10A human breast epithelial cells and primary human omental mesothelial cells after TGF-βtreatment (Figure S4A,B). Non-Coding RNA 2022, 8, x 4 of 28 Figure 1. Cont. Non-Coding RNA 2022,8, 62 4 of 27 Non-Coding RNA 2022, 8, x 4 of 28 Figure 1. Genomic context and expression profiles of Lnc-Nr6a1 and Nr6a1 genes. ( A ) Schematic illustration of the genomic location and transcript structure of the Lnc-Nr6a1 gene embedded within the third intron of the Nr6a1 gene. The annotated nascent and processed transcripts of Lnc-Nr6a1 (lnc-Nr6a1-1 and lnc-Nr6a1-2) and lnc-pri-miR-181a2/b2 are shown. The red arrows indicate the transcription orientation. ( B ) Schematic representation of spliced lnc-pri-miR-181a2/b2 transcript and ( C ) electrophoretic gel showing PCR products generated with a forward primer located in exon2 and reverse primers located in miR-181a2 and mir181b2, respectively. ( D ) Rate of poly(A − ) RNA relative to poly(A + ) RNA for the indicated transcripts, quantified by RT-qPCR. ( E ) Relative levels of Nr6a1 mRNA in cells treated with TGFβ at the indicated times. Experiments were performed in triplicate samples and error bars represent S.D. ( F ) Relative levels of lnc-Nr6a1 isoforms in cells treated with TGFβ at the indicated times. ( G ) Expression of miR-181a2/b2 in cells treated with TGFβ for 24 h. Experiments were repeated twice in triplicate samples; error bars represent S.D. ( H , I ) relative expression of Nr6a1 mRNA and lnc-Nr6a1 isoforms, respectively, in a broad range of adult mouse tissues. Results are presented relative to a fixed reference sample (thymus and liver in ( H , I ), respectively). Experiments were performed in triplicate samples; error bars represent S.D. *** p< 0.001, ** p< 0.01 by two-tailed Student’s t-test. Non-Coding RNA 2022,8, 62 5 of 27 1 Figure 2. Signaling pathways involved in lnc-Nr6a1 isoforms upregulation by TGFβ . ( A ) NMuMG cells were transfected with DsiRNAs against Smad4 (DsiSmad4) or scramble DsiRNA (SRC) and treated with TGFβ for 2 h. Levels of lnc-Nr6a1-1 (top) and lnc-Nr6a1-2 (bottom) were measured by RT-qPCR analysis. Experiments were performed in triplicate samples; error bars represent S.D. ( B ) Effect of p38 kinase inhibitor, SB203580, on lnc-Nr6a1 isoforms upregulation. Cells were pretreated with 10 µ M inhibitor for 1 h and next treated with TGFβ for 2 h where indicated. Levels of lnc-Nr6a1-1 (top) and lnc-Nr6a1-2 (bottom) were measured by RT-qPCR analysis. Experiments were performed in triplicate samples; error bars represent S.D. ( C , D ). Effect of MAP kinase inhibitor U0126 and AKT inhibitor GSK690693, respectively, on lnc-Nr6a1 isoforms upregulation. NMuMG cells were pre-treated with 10 µ M inhibitor for 1 h prior to addition of TGFβ for 2 h where indicated. Levels of lnc-Nr6a1-1 (top) and lnc-Nr6a1-2 (bottom) were measured by RT-qPCR analysis. Experiments were Non-Coding RNA 2022,8, 62 6 of 27 performed in triplicate samples; error bars represent S.D. ( E ) Representative immunoblot (top) and densitometry analysis (bottom) for SMAD4, p38 kinase (phosphorylated p85 ribosomal kinase, p85), MAP kinase (phosphorylated ERK1/2, pERK1/2) and AKT kinase (AKT phosphorylated substrate, AKT Sub) are shown. β -actin was used for protein-loading normalization in SMAD4, p38 kinase and AKT kinase immunoblots. Total ERK1/2 were used as the protein-loading control in the ERK1/2 immunoblot. ( F ) Requirement of de novo protein synthesis for lnc-Nr6a1 isoforms upregulation by TGFβ . NMuMG cells pre-treated with 5 µ M of cycloheximide (CHX) for 1 h were stimulated with TGFβ for 2 or 24 h. Expression levels of lnc-Nr6a1 isoforms and SIP1 were measured by RT-qPCR analysis. Experiments were performed in triplicate samples; error bars represent S.D. *** p< 0.001, ** p< 0.01, ns, not significant by two-tailed Student’s t-test. Signaling pathways involved in lnc-Nr6a1 isoforms induction by TGFβ were investigated. Smad4 is a central mediator of the Smad-dependent canonical pathway. Two different Dicer-substrate short interfering RNAs were used for silencing Smad4 and the knockdown efficiencies were tested by Western blotting. Upregulation of lnc-Nr6a1 isoforms by TGFβ was not affected in Smad4-suppressed cells, indicating TGFβ -Smad signaling independency of TGFβ response (Figure 2A). TGFβ non-canonical pathways, extracellular signal-regulated kinases (ERKs), p38 mitogen-activated protein kinase (p38 MAPK) and protein kinase B (AKT) are activated very rapidly in TGFβ -treated NMuMG cells [ 15 ]. Blocking of p38 MAP kinase and AKT signaling pathways had no effect on TGFβ -upregulation of lnc-Nr6a1-1 (Figure 2B,D), whereas blocking the MEK-ERK1/2 signaling pathway inhibited its expression (Figure 2C). Remarkably, lnc-Nr6a1-2 expression was specifically abolished by GSK6906693, an inhibitor of AKT (Figure 2D). Taken together these results indicate that each isoform is regulated by a different signaling pathway. The early upregulation of lnc-Nr6a1-1/2 isoforms suggested an active role in the start of the EMT program. To determine whether they were direct targets of ERK and AKT signaling pathways, expression levels of lnc-Nr6a1-1/2 isoforms were analyzed in cells treated with TGF-βin the presence or absence of cycloheximide, an inhibitor of protein synthesis. RT-qPCR results showed upregulation of both isoforms in the presence of cycloheximide, whereas upregulation of an indirect target control, SIP1, was blocked (Figure 2E). These data suggest that lnc-Nr6a1-1 and lnc-Nr6a1-2 isoforms are direct targets of ERK1/2 and AKT pathways, respectively. 2.2. Lnc-Nr6a1 Depletion Reduces Cell Adhesion and Alters Gene Expression To examine the physiological relevance of Lnc-Nr6a1 expression in EMT, we used CRISPR-Cas9 technology to remove Lnc-Nr6a1 transcription. NMuMG cells were edited by CRISPR using two pairs of single guide RNAs (sgRNAs) located in the promoter and first exon of Lnc-Nr6a1, respectively, obtaining a deletion of 600 bp (Figure 3A). Complete inhibition of lnc-Nr6a1 isoforms expression was achieved in homozygous clones (Figure 3B,C). Furthermore, disruption of the Lnc-Nr6a1 host gene expression affected the mi181a2/b2 expression (Figure 3D). It should be noted that expression of identical mature miR-181a and miR-181b, encoded by mir-181a1 and mir-181b1 genes on chromosome 1, was not affected by TGFβ treatment. Previous chromatin immunoprecipitation followed by deep sequencing (ChIP-seq) assays in the same cell line [ 16 ] showed a remarkable H3K4me3 and H3K27ac-enriched region with high chromatin accessibility (via ATAC-seq) around the transcription start site of the Lnc-Nr6a1 gene. Neither H3K4me3 and H3K27ac enrichment nor chromatin accessibility were found in the miR181a2/b2 region (Figure S5A). In addition, querying the PanCancer Atlas expression data reveals a strong co-expression relationship between Lnc-Nr6a1 and embedded miR-181a2/b2 in different tumors (Figure S5B). Altogether, these results support that up-regulation of miR-181a2/b2 and Lnc-Nr6a1 after TGFβ treatment are driven by activation of the same promoter. To reveal the functional importance of the Lnc-Nr6a1 transcripts, we performed transcription profiling of the LncNr6a1-depleted cells. Lnc-Nr6a1 knockout resulted in statistically significant changes in the expression levels of 218 genes (adjusted p-value < 0.05 and |log 2 FC| > 0.5) compared with the control cells; among them 95 and 123 were downregulated and upregulated, re- Non-Coding RNA 2022,8, 62 7 of 27 spectively (Table S1 and Figure 3E). Some of these changes were confirmed by RT-qPCR, as downregulation (>100-fold) of Dsg2,Fam111a,Mal2,FoxF1 and upregulation of Prune,Pkp1, Adgrl3, (Figure S6). Gene ontology analysis of the downregulated genes in Lnc-Nr6a1 −/− cells showed an enrichment in genes involved in cell adhesion and the glycolytic process (Figure 3F and Table S2). Next, we investigated the effect of Lnc-Nr6a1 knock-down on the adhesion capacity of NMuMG cells to substrate and cells. Lnc-Nr6a1-depleted cells showed a lower capacity to adhere to the substrate; this effect was observed over a long and short time (Figure 4A,B). Furthermore, neither cell cycle changes nor alterations in proliferation were observed in Lnc-Nr6a1-depleted cells (Figure S7A,B). In order to determine the effect of Lnc-Nr6a1 absence on cell-cell adhesion, monolayers of NMuMG cells were incubated with calcein-labelled Lnc-Nr6a1-depleted cells or control cells for 2 h. Flow cytometry analysis showed a lower ability of Lnc-Nr6a1-depleted cells to adhere to cells (Figure 4D,E). The loss of adhesion capacity to substrate and cells were partially recovered after expressing lnc-Nr6a1-1 isoform (Figure 4C–E). Together, the combination of lncRNA profiling and functional assays identified Lnc-Nr6a1 as a lncRNA involved in cell adhesion to substrate and cells. Since Lnc-Nr6a1 is induced early by TGFβ , we studied whether expression changes produced by TGFβ were dependent on the presence of Lnc-Nr6a1. We analyzed the transcriptomic profiles of the control cells versus Lnc-Nr6a1-depleted cells after 2 h of TGFβ treatment (Tables S3 and S4). In total, 895 genes were upregulated and 747 genes downregulated in the control cells and 641 and 459 genes, respectively, in the Lnc-Nr6a1depleted cells (adjusted p-value < 0.05 and |log 2 FC| > 0.5). We found 44% and 27% of upregulated and downregulated genes, respectively, by TGFβ were common in both types of cells; therefore, their regulation was independent of the presence or absence of Lnc-Nr6a1. These genes were enriched in those involved in EMT, phosphatidylcholine biosynthetic process, DNA replication checkpoint and chromatin silencing (Figure 5A,B). This result indicates that 56% and 73% of genes induced or inhibited, respectively, by TGFβ are dependent on the presence of Lnc-Nr6a1 and slightly enriched in genes involved in histone modification and ribosomal RNA maturation. Likewise, Lnc-Nr6a1 depletion caused induction or inhibition of new genes by TGFβ (39% and 55%, respectively) enriched mainly in meiotic chromosome condensation, DNA replication initiation and negative regulation of chromatin silencing. Together, these data indicate that Lnc-Nr6a1 depletion affects differential gene expression mediated by TGFβ ; however, expression of genes involved in EMT was independent on the presence of Lnc-Nr6a1. Forced expression of lnc-Nr6a1 isoforms neither revealed apparent morphological changes in cells nor significant changes in expression levels of the EMT markers. Furthermore, neither cell cycle nor proliferation were affected in isoform-overexpressing cells (Figure S8). However, woundhealing assays revealed that cells overexpressing either of the two isoforms migrated much faster than control cells, but the effects were not additive. Notably, cell migration was not affected by Lnc-Nr6a1 depletion (Figure 5C–E, Video S1). Non-Coding RNA 2022,8, 62 8 of 27 Non-Coding RNA 2022, 8, x 8 of 28 Figure 3. Deletion of a Lnc-Nr6a1 fragment in NMuMG cells and expression profile. (A) Scheme showing the 600 bp deleted fragment of Lnc-Nr6a1 deletion in NMuMG cells using CRISPR-Cas9 technology. Sites of cleavage by Cas9 in the promoter and first exon regions are indicated; primers (green arrows) for clones analysis are shown (B) Representative gel identifying non-deletion (control, clones 1, 7 and 8) monoallelic (clone 2, 3, 4, 5 and 6) and biallelic clones (clone 9). (C) Expression levels of lnc-Nr6a1 isoforms in different clones were measured by RT-qPCR analysis. (D) Expression of miR-181a/b species in control and Lnc-Nr6a1-depleted cells after 24 h of TGF-β treatment or untreated. Experiments were repeated twice in triplicate samples; error bars represent S.D. *** p < 0.001, ** p < 0.01, * p < 0.05, ns, not significant by two-tailed Student’s t-test. Y-axis of last panel (down right) is labeled 181a-5p because the isoforms miR-181a1-5p and miR-181a2-5p are identical. (E) Volcano plot for differentially expressed genes in Lnc-Nr6a1-depleted cells versus control cells. Genes upregulated with more than a 1.5-fold change with a p-value < 0.05 are depicted in red boxes and those downregulated with identical fold change and p-value are in green boxes. (F) Gene ontology enrichment analysis of downregulated genes in Lnc-Nr6a1-depleted cells. Figure 3. Deletion of a Lnc-Nr6a1 fragment in NMuMG cells and expression profile. ( A ) Scheme showing the 600 bp deleted fragment of Lnc-Nr6a1 deletion in NMuMG cells using CRISPR-Cas9 technology. Sites of cleavage by Cas9 in the promoter and first exon regions are indicated; primers (green arrows) for clones analysis are shown ( B ) Representative gel identifying non-deletion (control, clones 1, 7 and 8) monoallelic (clone 2, 3, 4, 5 and 6) and biallelic clones (clone 9). ( C ) Expression levels of lnc-Nr6a1 isoforms in different clones were measured by RT-qPCR analysis. ( D ) Expression of miR-181a/b species in control and Lnc-Nr6a1-depleted cells after 24 h of TGFβ treatment or untreated. Experiments were repeated twice in triplicate samples; error bars represent S.D. *** p< 0.001, ** p< 0.01, * p< 0.05, ns, not significant by two-tailed Student’s t-test. Y-axis of last panel (down right) is labeled 181a-5p because the isoforms miR-181a1-5p and miR-181a2-5p are identical. ( E ) Volcano plot for differentially expressed genes in Lnc-Nr6a1-depleted cells versus control cells. Genes upregulated with more than a 1.5-fold change with a p-value < 0.05 are depicted in red boxes and those downregulated with identical fold change and p-value are in green boxes. ( F ) Gene ontology enrichment analysis of downregulated genes in Lnc-Nr6a1-depleted cells. Non-Coding RNA 2022,8, 62 9 of 27 Non-Coding RNA 2022, 8, x 9 of 28 Figure 4. Lnc-Nr6a1 depletion affects cell adhesion. Scanned 60-mm Petri dishes with fixed colonies subjected to crystal violet staining assays, (A,B) control cells and Lnc-Nr6a1-depleted cells, (C) LncNr6a1-depleted cells and Lnc-Nr6a1-depleted cells overexpressing lnc-Nr6a1-1 isoform. Cells were plated on dishes and incubated for indicated times. Stained adherent cells were solubilized with 1% SDS at room temperature for 30 min and quantified at OD 590 nm. Experiments were performed in triplicate, and data are expressed as the mean ± S.D. from three independent experiments. (D) and (E) Flow cytometric analysis of control, Lnc-Nr6a1-depleted and Lnc-Nr6a1-depleted cells, overexpressing lnc-Nr6a1-1 calcein-labeled cells. Labeled cells were added to a confluent monolayer of unstained NMuMG cells incubated for 2 h and adherent cells quantified by flow cytometry analysis. The bar graph shows mean ± S.D. of six independent experiments, *** p < 0.001, ** p < 0.01 via twotailed Student’s t-test. Figure 4. Lnc-Nr6a1 depletion affects cell adhesion. Scanned 60-mm Petri dishes with fixed colonies subjected to crystal violet staining assays, ( A , B ) control cells and Lnc-Nr6a1-depleted cells, ( C )LncNr6a1-depleted cells and Lnc-Nr6a1-depleted cells overexpressing lnc-Nr6a1-1 isoform. Cells were plated on dishes and incubated for indicated times. Stained adherent cells were solubilized with 1% SDS at room temperature for 30 min and quantified at OD 590 nm. Experiments were performed in triplicate, and data are expressed as the mean ± S.D. from three independent experiments. ( D , E ) Flow cytometric analysis of control, Lnc-Nr6a1-depleted and Lnc-Nr6a1-depleted cells, overexpressing lnc-Nr6a1-1 calcein-labeled cells. Labeled cells were added to a confluent monolayer of unstained NMuMG cells incubated for 2 h and adherent cells quantified by flow cytometry analysis. The bar graph shows mean ± S.D. of six independent experiments, *** p< 0.001, ** p< 0.01 via two-tailed Student’s t-test. Non-Coding RNA 2022,8, 62 16 of 27 Non-Coding RNA 2022, 8, x 17 of 28 phophatedeshydrogenase. The results are the median of three technical replicates; error bars represent S.D. (E) Subcellular localization of lnc-Nr6a1 isoforms. Expression of Hprt, lnc-Nr6a1-1, lncNr6a1-2, U3 and Xist in cytoplasmic, nuclear soluble and nuclear insoluble fractions of NMuMG cells. The graph is an average of three technical replicates; error bars represent S.D. Our finding that glycolytic proteins ALDOA, ENO1, PKM, GAPDH, along with LDHA, interact with lnc-Nr6a1-1 is outstanding. Covalent bonds between lnc-Nr6a1-1 and interacting proteins are direct because they were created by UV crosslinking. This result strongly suggested that lnc-Nr6a1-1 could act as a scaffold molecule to gather glycolytic proteins to promote glycolysis by substrate channeling. To test this hypothesis, we measured the glycolysis metabolic process in the control and Lnc-Nr6a1-depleted cells using the Seahorse Analyzer, which provides accurate measurements of glycolytic rates for basal conditions and compensatory glycolysis following mitochondrial inhibition. We found that the knockout of Lnc-Nr6a1 significantly reduced basal glycolysis and compensatory glycolysis and that these effects were all reverted by overexpression of the lnc-Nr6a1-1 isoform (Figure 8A,B). Figure 8. Defective glycolysis in Lnc-Nr6a1-depleted cells. (A) Proton Efflux Rate derived from glycolysis (glycoPER) of the control, Lnc-Nr6a1-depleted cells and Lnc-Nr6a1-depleted cells overexpressing the lnc-Nr6a1-1 isoform. Rot/AA Rotenone/antimycin, 2-DG 2-Deoxy-D-glucose. (B) Plots of glycoPER quantification corrected using total µg of protein. GlycoPER is expressed as pmol/min/µg protein. Data from five independent experiments are presented as mean ± S.D. *** p < 0.001, ** p < 0.01 by two-tailed Student’s t-test. (C) Enrichment of glycolytic enzymes after immunoprecipitation with enolase-1. The percent change with respect to the average spectral count for the corresponding control group is indicated. A two-group, two-tailed Student’s t-test was used to determine the statistical significance of differences between the control (C1–3) and Lnc-Nr6a1-depleted Figure 8. Defective glycolysis in Lnc-Nr6a1-depleted cells. ( A ) Proton Efflux Rate derived from glycolysis (glycoPER) of the control, Lnc-Nr6a1-depleted cells and Lnc-Nr6a1-depleted cells overexpressing the lnc-Nr6a1-1 isoform. Rot/AA Rotenone/antimycin, 2-DG 2-Deoxy-D-glucose. ( B ) Plots of glycoPER quantification corrected using total µ g of protein. GlycoPER is expressed as pmol/min/ µ g protein. Data from five independent experiments are presented as mean ± S.D. *** p< 0.001, ** p< 0.01 by two-tailed Student’s t-test. ( C ) Enrichment of glycolytic enzymes after immunoprecipitation with enolase-1. The percent change with respect to the average spectral count for the corresponding control group is indicated. A two-group, two-tailed Student’s t-test was used to determine the statistical significance of differences between the control (C 1–3 ) and Lnc-Nr6a1-depleted cell (K 1–3 ) samples. GAPDH, glyceraldehyde 3-phophatedeshydrogenase; PKM, pyruvate kinase; ALDOA, aldolase; LDHA, lactate dehydrogenase; PGK, phosphoglycerate kinase; HK, hexokinase; PGAM, phosphoglycerate mutase; TPI, triosephosphate isomerase ( D ) A proposed model for the role of lnc-Nr6a1-1 as a scaffold molecule involved in the formation of a glycolytic complex. F1,6BP, fructose-1,6-biphosphate; GA3P, 3-phosphoglycerate; 1,3BPG, 1,3-bisphosphoglycerate; 3-PG, 3-phosphoglycerate; 2-PG, 2phosphoglycerate; PEP, phosphoenolpyruvate. 3. Discussion In this study, we analyzed a lncRNA, Lnc-Nr6a1, which is induced early and abundantly during EMT. Two main isoforms are generated in response to TGFβ , with very similar expression levels. The expression of each one is regulated by different pathways: the lnc-Nr6a1-1 isoform by MEK-ERK1/2 and lnc-Nr6a1-2 isoform by AKT, routes that are simultaneously activated by TGFβ , and that would indicate that the isoforms could be involved in specific processes that respond to each of these routes. Each isoform has a polyadenylated transcript, but in the case of the lnc-Nr6a1-1 isoform it is also present as a non-polyadenylated precursor containing processed exons, miR-181a2 and miR-181b2 Non-Coding RNA 2022,8, 62 17 of 27 genes; as well as genomic sequences between the 3 0 -end of polyadenylated lnc-Nr6a1-1 and 5 0 -end of the miR-181a2 gene and the genomic sequence between both miRNAs. The transcriptional termination of the non-polyadenylated isoform and processing of pre-miR181a2 and pre-miR-181b2 would be mediated by the microprocessor complex [ 21 , 22 ]. Studies reported that the cleavage of the precursor transcript by Drosha occurs cotranscriptionally and sometimes even before the splicing of introns [ 23 , 24 ]; however, our results indicate that the cleavage of the non-polyadenylated lnc-Nr6a1-1 transcript by Drosha occurs after splicing of the introns. Regarding the resulting lncRNA molecule after processing by Drosha of the pre-miRNAs, the analysis of the UCSC genome browser shows the absence of ESTs between the 3 0 -end of polyadenylated lnc-Nr6a1-1 and 5 0 end of miRNA loci suggesting that Lnc-Nr6a1 non-polyadenylated mature transcript resulting from processing by Drosha is degraded [ 21 ]; therefore, lnc-Nr6a1-1 and lnc-Nr6a1-2 isoforms and miR-181a2 and miR-181b2 would be the molecules generated from the Lnc-Nr6a1 gene. The presence of polyadenylated and non-polyadenylated forms would make it possible to regulate the expression of these molecules, allowing high levels of one of them to be achieved without concomitant generation of high levels of another unwanted one. As has been described for other miRNA-host lncRNAs [ 11 , 22 , 25 ], Lnc-Nr6a1 carries out specific functions that are independent of its role as a miRNA precursor, thus the loss of adhesion capacity shown by Lnc-Nr6a1-depleted cells is rescued by exogenous expression of the lnc-Nr6a1-1 isoform; in the same way, the glycolytic activity in Lnc-Nr6a1-depleted cells reaches levels similar to those of the control cells when overexpressing the lnc-Nr6a1-1 isoform; and also, overexpression of any of the polyadenylated isoforms increases cell mobility and invasiveness. However, anoikis resistance only increases when miR-181a2 and miR-181b2 are expressed. Therefore, the Lnc-Nr6a1 gene, in addition to providing miR-181a2/b2 molecules, generates polyadenylated lncRNA molecules with independent functions. The in vivo study of proteins interacting with the lnc-Nr6a1-1 isoform reveals that this isoform interacts with different proteins, some of them participating in the same process or mechanism, suggesting that lnc-Nr6a1-1 could act as a scaffold molecule by recruiting or titrating the interacting proteins. Lamin A/C is the most enriched lnc-Nr6a11-interacting protein. Lamin A/C is a structural component of the nuclear lamina that regulates genome organization and gene expression. Lamin A/C associates with chromatin through large domains termed lamina-associated domains or LADs, which are located at the nuclear periphery [ 26 ]; however, lnc-Nr6a1-1 does not interact with DNA. Therefore, its interaction with Lamin A/C would take place in regions where Lamin A/C does not interact with DNA, such as the nucleoplasm, where significant levels of A-type lamins have been found [ 27 ]. The LADs present in the cell change as gene expression changes; however, in Lnc-Nr6a1-depleted cells only partial changes in LADs are detected, which do not correspond to gene expression changes detected in the Lnc-Nr6a1-depleted cells. This would indicate that lnc-Nr6a1-1 carries out functions in the nucleus, unknown at the moment, but it would not act as a transcriptional regulator. lnc-Nr6a1-1 interacts directly with the proteins plakophilin, plakoglobin and desmoplakin; the three main components of the desmosome [ 28 ]. Desmoplakin couples intermediate filaments to the desmosome and its amino-terminus binds directly to plakoglobin and the plakophilin [ 29 ]. The direct interaction of lnc-Nr6a1-1 with these proteins marks it as an additional component of the desmosome that could facilitate the formation of the complex. This could explain the cell-cell adhesion decrease in Lnc-Nr6a1-depleted cells and subsequent recovery after exogenous expression of the lnc-Nr6a1-1 isoform. It is increasingly evident that glycolysis proteins associate to form multienzyme complexes, especially under stress conditions to meet excessive energy demand. Studies on yeast have revealed that glycolysis enzymes colocalize into non-membrane-bound granules, named glycolytic bodies or G bodies, in response to hypoxia [ 30 ]; also, in neurons of Caenorhabditis elegans, analogous granules are formed to sustain changes in the activity of synapses [ 31 ]. These structures are formed by phase separation and RNA molecules appear to be responsible for concentrating and sequestering protein components through multiple binding sites [ 32 , 33 ]. A large number Non-Coding RNA 2022,8, 62 18 of 27 of studies have shown that lncRNAs can affect genes involved in glucose metabolism by directly regulating the glycolytic enzymes and glucose transporters or indirectly modulating the signaling pathways [ 34 ]. We have found that ENO1, ALDOA, GAPDH, and PKM glycolytic enzymes, along with LDHA, interact in vivo directly with lnc-Nr6a1-1 isoform in non-transformed NMuMG cells in normal conditions. Glycolytic metabolism is affected in Lnc-Nr6a1-depleted cells; thus, these cells showed lower basal and reserve glycolytic activity than control cells; but the glycolytic activity was recovered upon exogenous expression of the lnc-Nr6a1-1 isoform. We propose that lnc-Nr6a1-1 act as a scaffold molecule interacting directly with these enzymes. We must underline the fact that these enzymes were coprecipitated with antibody against ENO1 irrespective of the presence of lnc-Nr6a1-1; however, in Lnc-Nr6a1-depleted cells, coprecipitated enzymes were markedly reduced, indicating that lnc-Nr6a1-1 supports formation of a multi-protein complex of glycolytic enzymes and that this results in enhanced catalytic efficiency. Coimunoprecipitation of this pool of enzymes from UV-crosslinked Lnc-Nr6a1-depleted cells indicates that other RNAs could jointly contribute to the glycolytic complex formation. In fact, gLINC lnc-RNA was recently reported to act as a backbone for complex formation between PGK1/ENO1/ and PKM2, along with LDHA, promoting glycolytic flux and ATP production [ 35 ]; in the same way NEAT1 lncRNA forms a scaffold bridge for the assembly of the glycolytic complex PGK1, PGAM and ENO1 promoting a glycolytic state in breast cancer that is associated with more invasive and higher-grade tumors [ 36 ]. The contribution of other lncRNAs in the formation of the glycolytic complex would support that the enzymes TPI1, PGK1 and PGAM1 are co-immunoprecipitated by ENO1, despite not being present in the lnc-Nr6a1-1 interactome. A hallmark of cancer cells is metabolic reprogramming to generate energy through increased glycolysis even in the presence of oxygen, known as the Warburg effect [ 37 , 38 ]. High levels of Lnc-Nr6a1 are observed in most of the tumors analyzed (Figure S11), which could be associated with the formation of multienzyme complexes and increased glycolytic activity in cancer cells. Our results show different functions for Lnc-Nr6a1. On the one hand, by means of its non-polyadenylated transcript, Lnc-Nr6a1 serves as a miRNA reservoir, giving rise to miRNAs miR-181a2 and miR-181b2; on the other hand, polyadenylated lnc-Nr6a1-1 transcript is involved in cell adhesion and glycolytic metabolism. Additional non-overlapping mechanisms for the lnc-Nr6a1-2 isoform are not ruled out. Further explorations of the isoform-specific interactome will unveil the full biological activities of this lncRNA. 4. Materials and Methods 4.1. Reagents The following antibodies were used in our study: anti-ERK1/2 (Cat# 61-7400; Thermo Fisher Scientific, Waltham, MA, USA), anti-phospho-ERK1/2 (9101; Cell Signaling Technology, Danvers, MA, USA), anti-phospho-p70 S6 kinase (Cat# 9206; Cell Signaling Technology), anti-phospho (Ser/Thr) AKT substrate (Cat# 9611; Cell Signaling Technology), anti-phospho-p85 (Cat# 9206; Cell Signaling Technology), anti-Smad4 (Cat# sc-7966; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-E-cadherin (Cat# 610181; BD Transduction Laboratories, BD Biosciences, San Jose, CA, USA), anti-N-cadherin (Cat# 610921; BD Transduction Laboratories), anti-Vimentin (Cat# sc-32322; Santa Cruz), anti-Snail1 (Cat# C15D3; Cell Signaling Technology), anti-Enolase1 (Cat# 3810; Cell Signaling Technology), anti-GAPDH (Cat# sc-47724; Santa Cruz), anti-ALDOA (Cat# 11217-1-AP; Proteintech, Proteintech Europe Ltd, Manchester, UK), anti-Pyruvate kinase (Cat# 3106; Cell Signaling Technology), anti-Lamin A/C (Cat# sc-376248; Santa Cruz), anti-g-Catenin (Cat# A0963; ABclonal, Woburn, MA, USA), anti-Plakophilin (Cat# sc-33636; Santa Cruz), antiβ -Actin (Cat# A1978; Sigma-Aldrich, St Louis, MO, USA). GSK690693, U0126 and SB-203580 were purchased from Selleck Chemicals (Houston, TX, USA). TGFβ was purchased from PeproTech (London, UK). Non-Coding RNA 2022,8, 62 19 of 27 4.2. Cell Culture NMuMG cells were grown in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum, 2 mM L-glutamine, antibiotics (50 U/mL penicillin, 50 lg/mL streptomycin) and insulin (10 µg/mL) at 37 ◦C in a 5% CO2humidified, 95% air incubator. 4.3. Lentiviral Production and Infection Assay Lentiviral production and infection assays were performed as described previously [ 5 ]. For ectopic expression of lnc-Nr6a1-1 or lnc-Nr6a1-2, NMuMG cells were infected with pHRSIN-DUAL-lnc-Nr6a1-1 or lnc-Nr6a1-2 lentiviral supernatants (MOI 2), respectively, containing 4 µ g/mL polybrene. The dual-promoter lentivector pHRSIN-DUAL (also known as pHRSIN-CSGWdINotI_pUb_Em) was kindly provided by Mary K. Collins (Okinawa Institute of Science and Technology, Okinawa, Japan). 4.4. Western Blot Analysis Protein was extracted with a RIPA buffer and western blotting was performed according to the standard protocols. Signals were detected with an ECL kit (GE Healthcare, Buckinghamshire, UK) and visualized and quantified using the ChemiDoc MP Imaging system (Bio-Rad, Hercules, CA, USA). 4.5. Proliferation, Migration and Invasion Assays For growth curves, cells were harvested and transferred into 16-well E-plates, which contained electrodes integrated into the bottom surfaces of each well to measure cell index based on impedance using the xCELLigence System (Roche, Indianapolis, IN, USA). First, 100 µ L of cell culture media was first added to each well at 37 ◦ C for 30 min to equilibrate the conductors to the media. Then, 8 k, 4 k, 2 k and 1 k of cells were added per well, and the program was set to conduct readings every 30 min for 95 h. Cell migration was measured by using Culture-Inserts (IBIDI, Martinsried, Germany). The culture-inserts were transferred to six-well plates, and the cells were seeded at a density of 7 × 10 4 /mL in each well of culture-inserts and cultured in phenol red-free complete medium. After 24 h of incubation, the culture-inserts were removed, and a 400 µ m cell-free gap was created. Cell migration was observed with a Leica DMI6000 inverted microscope equipped with a Hamamatsu ORCA-ER camera using LEICA N PLAN 10 × , /20 × /0.25 objectives, and recorded every 20 min for 23 h. Image processing was carried out using the Leica (LAS) and Adobe Photoshop software. Quantification of the cell surface was performed using the multiwavelength cell-scoring module of Metamorph Offline software and the WimScratch Wound Healing Module (WIMASIS, Munich, Germany) program. Transwell invasion assays were performed using Transwell chambers (24 well, 8 µ m pore size; Cell Biolabs, San Diego, CA, USA) coated with basement membrane. The cells were allowed to grow to subconfluency and were serum-starved for 24 h. After detachment with trypsin, the cells were washed with PBS, resuspended in serum-free medium and 5 × 10 4 cells were added to the upper chamber. The complete medium was added to the bottom well of the chamber. The cells that had not migrated were removed from the upper face of the filters using cotton swabs, and the cells that had migrated to the lower face of the filters were fixed with 3.7% formaldehyde, permeabilized with 100% methanol and stained with 0.05% crystal violet. Invasive cells were solubilized with 1% SDS at room temperature for 30 min, and quantified at OD 590 nm. 4.6. Immunofluorescence Microscopy Cells grown on coverslips were fixed in 4% paraformaldehyde/phosphate-buffered saline at room temperature for 15 min and then permeabilized by incubation in 0.01% Triton X-100 in PBS. After fixation, the coverslips were blocked with 3% BSA in PBS for 45 min and incubated with primary antibody for 1 h followed by appropriate Alexa488and Alexa594-conjugated secondary antibodies or rhodamine phalloidin (Molecular Probes, Eugene, Oregon USA) for 1 h at room temperature. The coverslips were counterstained Non-Coding RNA 2022,8, 62 20 of 27 with DAPI (Sigma-Aldrich) and mounted with the anti-fade agent Prolong Gold (Molecular Probes). Images were acquired with a Leica DM6000B microscope. Data were processed with Adobe Photoshop CS4 (Adobe Systems, San José, CA, USA). 4.7. RNA Isolation and RT-qPCR Total RNA was isolated using TRIzol (Invitrogen, Life Technologies, Karlsrube, Germany), treated with TURBO DNase (Invitrogen), and reverse-transcribed with a mix of oligo(dT) 20 and random hexamers using SuperScript III reverse transcriptase (Invitrogen). RT-qPCR was performed using iTaq Universal SYBR Green Supermix (Bio-RAD) and analyzed on an Applied Biosystems 7500 Fast-Real-Time PCR System. Expression levels of mRNAs were normalized to Hprt levels. According to the published data on miRNAs expression in NMuMG cells by TGFβ treatment [ 39 ], we used the miR-425-5p gene to normalize miRNAs expression. 4.8. Poly(A)+and Poly(A)−RNA Separation Separation of Poly(A) + and Poly(A) − RNA was essentially performed as described [ 40 ]. DNAse-treated total RNA was incubated with oligo(dT) magnetic beads (Dynabeads, Invitrogen) to isolate poly(A) + RNAs, which were bound to the beads, or poly(A)-RNAs, which were present in the flow through after incubation. Selection with oligo (dT) magnetic beads was performed three times to ensure pure poly(A) + and poly(A) − populations. The poly(A) − RNA population was further processed with the Ribo-Zero magnetic kit (Epicentre, Epicentre Biotechnologies, Madison, WI, USA) to deplete most of the abundant ribosomal RNA. 4.9. In Vitro Poly(A) Tailing and RACE To determine the 3 0 end(s) of the lnc-NR6a1 precursor, in vitro poly(A) − tailing of total RNA was carried out with the poly(A) Polymerase Tailing Kit (Epicentre) according to the manufacturer’s protocol. 3 0 and 5 0 RACE were performed using the FirstChoice RLM-RACE kit (Invitrogen) following the manufacturer’s protocol. The RT-PCR primer sequences are listed in Table S7. 4.10. RNA Isolation from Mouse Tissues Organs from normal C57BL/6 mice were dissected and immediately frozen in liquid nitrogen and stored at −80 ◦C. To isolate RNA, 40–60 mg of frozen tissue specimens were cut in small pieces and transferred to a tube containing 1 mL of TRIzol Reagent (Invitrogen). Next, they were mechanically homogenized using a Pro250 homogenizer (PROScientific, Oxford, CT, USA) and total RNA was extracted according to the manufacturer’s instruction. 4.11. Cell Fractionation The separation of cytosolic, chromatin and soluble nuclear fractions was carried out as previously described [ 41 ]. RNA was extracted from each fraction using a TRIzol reagent (Invitrogen). 4.12. RNA-Seq Analysis Total RNA was isolated using TRIzol (Invitrogen), depleted of DNA by DNase treatment (TURBO DNase, Invitrogen). Libraries were prepared with the TruSeq Stranded mRNA kit (Illumina, San Diego, CA, USA) and sequencing was performed with a Novaseq system (Illumina) with 75 bp single-end reads with the Genomic Unit of CABIMER (Sevilla, Spain). Two biological replicates for each condition were sequenced. Reads were aligned to mouse genomes (GRCm38/mm10 and NCBI37/mm9) using the subjunc function from the Rsubread package. The downstream analysis was performed on .bam files with duplicates removed using the samtools (v0.1.19) rmdup command. Differential gene expression analysis and statistics were performed using the DESeq2 Bioconductor. Differentially expressed genes with p-adjusted values < 0.05 and Log 2 FC > 0.5 (upregulated genes) or Log 2 FC < − 0.5 Non-Coding RNA 2022,8, 62 21 of 27 (downregulated genes) were selected for further analysis. Gene ontology (GO) functional categories were analyzed using DAVID Bioinformatics Resources. Non-adjusted pvalues were used to determine the enrichment significance. 4.13. ChIP Sequencing ChIP assays and RNA immunoprecipitation were performed as previously reported [ 42 ]. NMuMG cells were crosslinked in 1% formaldehyde for 10 min at room temperature followed by the addition of glycine (125 mM final concentration) for 5 min. Nuclei were isolated using lysis buffer 1 (5 mM Pipes pH 8, 85 mM KCl, 0.5% NP-40, and complete protease inhibitor cocktail (Roche, Hoffmann-La Roche Inc., Nutley, NJ, USA)) and were lysed using lysis buffer 2 (1% SDS, 10 mM EDTA, 50 mM Tris–HCl pH 8.1, and complete protease inhibitor cocktail (Roche)). Chromatin was sheared into an average size of 500 bp by eight pulses of 30 s (30 s pause between pulses) at 4 ◦ C in the water bath sonicator Bioruptor (Diagenode, Liège, Belgium).Thirty micrograms of chromatin were diluted 1:10 in IP buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris–HCl pH 8.1, 167 mM NaCl, 1% sodium deoxycholate) and incubated overnight at 4 ◦ C in rotation with 5 µ g of monoclonal antibody anti-Lamin A/C (sc-376248; Santa Cruz) or anti-rabbit IgG control antibody (Sigma). Complexes were collected using Protein-A Dynabeads pre-blocked with BSA (New England Biolabs) and transfer RNA (Roche) and then washed with wash buffer 1 (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris–HCl pH 8.1, and 150 mM NaCl, 1% sodium deoxycholate), wash buffer 2 (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris–HCl pH 8.1, 500 mM NaCl, 1% sodium deoxycholate), wash buffer 3 (0.25 M LiCl, 1% NP-40, 1% sodium deoxycholate, 1 mM EDTA, 10 mM Tris–HCl pH 8.1), and twice with TE 1 × buffer (10 mM Tris–HCl pH 8.0, 1 mM EDTA). The complexes were eluted twice from the beads with elution buffer (1% SDS in TE 1 × buffer) by incubating 10 min at 65 ◦ C. The eluates and the inputs were incubated overnight at 65 ◦ C for decrosslinking and treated with Proteinase K for 1 h at 37 ◦ C. Chipped DNA was purified with phenol: chloroform extraction followed by ethanol precipitation and resuspended in Milli-Q water. The sequencing was performed with the Illumina HiSeq2000 system (Illumina) with 75 bp paired-end reads at the Genomic Unit of CABIMER (Sevilla, Spain). ChIP-seq reads for each condition were independently aligned against the MGSCv37/mm9 mouse reference genome using the align function from the Bioconductor Rsubread package (v1.28.1) with type = 1, TH1 = 2 and unique = TRUE parameters. Then a differential binding analysis was performed to identify Lamin Associated Domains (LADs) using the csaw (v1.12.0) and edgeR (v3.20.9) packages. Briefly, aligned reads were counted in bins of 25 kb along the genome using the windowCounts function and read coverage of each bin was normalized to library size using calcNormFactors. To perform differential binding analysis for each window using input as the control, a sequential number of functions were used: estimateDisp, glmFit and glmLRT. Finally, enriched windows were merged as they were overlapping or adjacent using the mergeWindows function. 4.14. RNA Immunoprecipitation RNA immunoprecipitation was performed after the formaldehyde crosslinking of cells. Cells were resuspended in the RIPA buffer and incubated for 30 min at 4 ◦ C and next homogenized by sonication (Digenode’s Bioruptor, 10 min, high power setting, 15 s on/30 s off). Precleared extracts were incubated overnight with either antibody anti-Lamin A/C, antiγ -Catenin, anti-ENO1, anti-ALDOA, anti-GAPDH or IgG (Sigma). Complexes were captured using Protein-A Dynabeads, washed four times for 5 min at 4 ◦ C with RIPA buffer and resuspended in Tris-HCl pH 7.0, 5 mM EDTA, 10 mM DTT and 1% SDS and next incubated at 70 ◦ C for 45 min to reverse the crosslinks. RNA was extracted using TRIzol (Invitrogen) according to the manufacturer’s protocol, reversed transcribed and subjected to PCR. Non-Coding RNA 2022,8, 62 22 of 27 4.15. CHIRP Chromatin isolation by RNA purification (ChIRP) was essentially performed as described [ 43 ]. Anti-sense oligo probes were designed at http://singlemoleculefish.com (accesssed on 4 August 2022) (Table S7). Two negative controls were used in this assay: LacZ antisense DNA probes were used in control cells, while lnc-Nr6a1-1 probes were used in Lnc-Nr6a1-depleted cells. Input and purified DNA were sequenced using the Illumina NextSeq 500 system (Illumina) with 75 bp paired-end reads at the Genomic Unit of CABIMER (Sevilla, Spain). ChIRP-seq reads for each condition were independently aligned against the MGSCv37/mm9 mouse reference genome using the align function from the Bioconductor Rsubread package (v1.28.1) with type = 1, TH1 = 2 and unique = TRUE parameters. Peak calling was performed using macs2 callpeak (v2.1.2) using input as the control data and 2620345972 bp as the effective genome size. Then, peaks were filtered using − log10(FDR) ≥ 10 criteria and those peaks that overlap with the blacklisted region of the genome were removed using bedtools subtract. 4.16. CRISPR-SAM-Mediated Activation of Lnc-Nr6a1 CRISPR activation of the Lnc-Nr6a1 expression was achieved by the Synergistic Activation Mediator (SAM) using the three-vector system from Addgene (Addgene, Watertown, MA, USA): lenti dCAS-VP64 (Addgene plasmid #61425), lenti MS2-P65-HSF1 v2 (Addgene plasmid #89308) and lenti MS2-sgRNA (Addgene plasmid #61427) (Addgene. NMuMG cells were infected with dCAS-VP64 and MS2-P65-HSF1 lentiviruses and selected for 7 days with blasticidin (5 µ g /mL) and hygromycin (200 µ g/mL). Gene-specific sgRNA targets were designed using online tools provided by IDT (Integrated DNA Technologies) and CRISPOR (http://crispor.org, accessed on 4 August 2022). Guides (Table S7) were designed within –300/+100 bp of the transcription start site (TSS) of the Lnc-Nr6a1 gene, with most guides within the proximal promoter ( ∼ 190 bp of the TSS), and they were cloned into the lenti sgRNA(MS2) plasmid. Cells were infected with lenti sgRNA(MS2) lentiviruses expressing Lnc-Nr6a1-targeting sgRNA and selected with 400 µ g/mL zeocin. The expression of lnc-Nr6a1 isoforms and miR-181a2 and miR-181b2 was then quantified with qRT-PCR. 4.17. CRISPR/Cas9-Mediated Deletion of Lnc-Nr6a1 The Alt-R CRISPR-Cas9 System (IDT) [ 44 ] was used to generate Lnc-Nr6a1-depleted NMuMG cells, according to the manufacturer’s protocol. Upstream and downstream guides were designed within − 600/ − 500 bp and +1000/+1100, respectively, of the TSS. Guide sequences are shown in Table S7. Successfully transfected cells were sorted by fluorescent-activated cell sorting (FACS) and individually distributed into 96-well plates. After 10–14 days, cells in each well were resuspended in 200 µ L of media and 100 µ L were plated into two separate 96-well flat-bottom plates. One of them was kept to allow clones to grow and the other one to screen each clone for deletion. Genomic DNA was isolated using the Purelink Genomic DNA Kit (Invitrogen) according to the manufacturer’s protocol. Deletions were analyzed by PCR and deletions amplicons were sequenced to identify the precise deletion. RNA was isolated from monoallelic and biallelic deletion clones and analyzed by RT-qPCR to quantify the Lnc-Nr6a1 expression. 4.18. iDRIP Experiments were performed as previously described [ 45 ]. Briefly, cells were crosslinked with 0.4 Jcm −2 of UV 254nm in cold PBS, harvested by scraping and pelleted. Crosslinked cells were resuspended in DNase I digestion buffer containing 50 mM Tris pH 7.5, 0.5% NP-40, 0.1% sodium lauroyl sarcosine, protease inhibitors, RNasin, 10 mM vanadil ribonucleoside and 600 U Turbo DNAse and incubated at 37 ◦ C for 15 min with rotation. Next, lysates were further supplied to the final concentrations of 1% sodium lauroyl sarcosine, 0.1% sodium deoxycholate, 0.5 M lithium chloride, 25 mM EDTA and 25 mM EGTA and incubated at 37 ◦ C for 5 min. The lysates were spun at 2500 rpm 10 min and the supernatans were collected. The pellets were resuspended in lysis buffer containing 50 mM Tris pH 7.5, Non-Coding RNA 2022,8, 62 23 of 27 0.5 M lithium chloride, 1% NP-40, 1% sodium lauroyl sarcosine, 0.1% sodium deoxycholate 20 mM EDTA and 20 mM EGTA, incubated on ice for 10 min, heated to 65 ◦ C for 5 min, and spun at room temperature; and the supernatant combined with the previous supernatants. The combined supernatants were pre-cleared by incubation with the washed MyOne streptavidin C1 magnetic beads (ThermoFisher) at room temperature for 30 min with rotation. The Streptavidin beads were then magnetically separated from the lysate samples using a Dynamag magnet (Life Technologies). Capture 3 0 biotin-TEG oligonucleotides and beads were mixed and incubated in 2 × binding buffer containing 10 mM Tris-HCl pH 7.5, 1 mM EDTA and 2 M NaCl at room temperature for 20 min, washed with 1 × binding buffer and then resuspended in lysis buffer. Pre-cleared lysates and oligonucleotides-conjugated beads were preheated to 65 ◦ C for 5 min, mixed and incubated at 65 ◦ C for another 15 min in the hybridization oven, followed by slowly reducing the temperature at 37 ◦ C and 1 h incubation. Beads with captured hybrids were washed three times at 37 ◦ C in wash buffer1 containing 50 mM Tris, pH 7.5, 0.3 M LiCl, 1% SDS, 0.5% NP-40, 1 mM DTT and protease inhibitors, followed by treatment at 37 ◦ C for 10 min with 20 U of Turbo DNase I in DNase digestion buffer supplemented in 0.3 M LiCl, protease inhibitors and RNasin. After washing two more times at 37 ◦ C with wash buffer1, the lysates were further washed at 37 ◦ C for 5 min in wash buffer2 containing 1% SDS, 1 mM DTT, 5 mM EDTA, 150 mM NaCl and 1 mM PMSF. The proteins were eluted at 70 ◦ C for 5 min in elution buffer containing 10 mM Tris, pH 7.5 and 1 mM EDTA. The eluted proteins eluted were lyophilized and stored at − 20 ◦ C until processing for mass spectrometry. As the negative control, LacZ (non-mammalian) capture probes were used. The Sequences of oligonucleotides are listed on Table S7. 4.19. Protein Identification Using Mass Spectrometry Proteins were in-gel digested as described [ 46 ]. Briefly, the eluted and dried-down proteins from the iDRIP experiment were subjected to SDS-PAGE gel and the whole proteome band upon entering the resolving gel was subjected to trypsin disgestion. The resulting peptides were analyzed by nanoliquid chromatography coupled to mass spectrometry, using a Q-Exactive HF mass spectrometer (ThermoFisher), for protein identification and quantification by spectral counting [ 47 ]. Peptide identification from MS/MS data was performed using the probability ratio method [ 48 ]. False discovery rates (FDR) of peptide identifications were calculated using the refined method [ 49 , 50 ]; 1% FDR was used as criterion for peptide identification. 4.20. Adhesion Assays Matrix adhesion assays were performed as described previously [ 51 ]. Briefly, 12-well plates were blocked with 1% bovine serum albumin for 1 h at 37 ◦ C. NMuMG cells (3 × 10 5 ) were added to the wells and then incubated for 1, 4, 6 and 8 h at 37 ◦ C. After three washings with PBS, the attached cells were fixed and stained with crystal violet. After extensive washing with PBS, bound dye was solubilized with 1% SDS, and the absorbance was read at a wavelength of 590 nm. Cell–cell adhesion assays were performed by resuspending NMuMG cells in serum-free medium and incubated with 5 µ m calcein-AM dye for 30 min at 37 ◦ C. After incubation, non-incorporated calcein-AM was removed by three washes with serum-free medium. 4 c10 4 calcein-AM-labeled cells were added to a confluent monolayer of unstained NMuMG cells grown in a 96-well plate. After 2 h incubation at 37 ◦ C, unbound calcein-AM-labeled cells were removed by washing with PBS. Adherent cells were dissociated from the culture plates and resuspended in PBS, and flow cytometrybased quantification of cells were carried out by FACS analysis. All adhesion experiments were done in triplicate and repeated at least three times. 4.21. Anoikis Induction and Flow Cytometry Anoikis was assayed by plating cells on polyHEMA-coated plates. A solution of 120 mg mL −1 polyHEMA (Sigma) in 100% ethanol was made and diluted 1:10 in 95% Non-Coding RNA 2022,8, 62 24 of 27 ethanol; 0.95 µ L mm −2 of this solution was overlaid onto 35-mm wells and left to dry in a heated dryer system for 12 h. Before use, wells were washed twice with PBS and once with DMEM. In all, 3.5 × 10 5 cells of each line, suspended in 2 mL DMEM containing methylcellulose 1% were incubated in the polyHEMA-coated wells for 18–24 h in a humidified (37 ◦ C, 5% CO 2 ) incubator. Cells were harvested and resuspended in 0.3 mL of PBS. Cells were fixed with ice-cold ethanol (70% final concentration), resuspended in 300 µ L solution of 50 µ g/mL propidium iodide and 250 µ g/mL DNase-free RNase in PBS, and incubated for 30 min at 37 ◦ C. For flow cytometric analysis, at least 10,000 cells were evaluated using a FACSCalibur ™ cytometer. Cell-cycle distribution and Sub-G 1 fraction were determined and quantified using the CellQuest-Pro software. 4.22. Seahorse Assay XFe24 Extracellular Flux Analyzer (Agilent, Santa Clara, CA, USA) was used to determine glycolysis metabolism. Cells were plated in 24-well (1.5 × 10 4 cells/well) Seahorse Assay plates, grown in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum, L-glutamine, antibiotics and insulin (10 µ g/mL) and incubated overnight at 37 ◦ C in a 5% CO 2 humidified, 95% air incubator. The sensor cartridge was hydrated adding 500 µ L of XF Calibrant Solution (Agilent) at 37 ◦ C in a CO 2 -free incubator overnight. GlycoPER was determined using the Agilent Seahorse XF Glycolytic Rate Assay Kit (Agilent, Cat No: 1033344). Data were analyzed by software Seahorse XFe (Agilent). All measurements were normalized with total protein concentration on each well. Each assay was run with 6 replicates per each condition. 4.23. Analysis of Tumor Data Sets Data on co-expression analysis for miR181A2HG (human Lnc-Nr6a1) and hsa-miR181a23p levels from 9 tumor types (4179 samples) were obtained from the TCGA project via the Genomic Data Commons Data Portal. Nomenclature, cancer full name and sample number are shown in Figure S5. GEPIA data were used to obtain miR181A2HG (human Lnc-Nr6a1) expression profiles of 18 types of human cancer and the corresponding adjacent normal tissues. 4.24. Statistical Analysis Data were analyzed by one-way ANOVA and Student’s t-test comparison, using GraphPad Prism 5 (Graphpad Software, La Jolla, CA, USA). Significant p-values are indicated with asterisks as follows: * p< 0.05, ** p< 0.01, and *** p< 0.001. The probabilities of overlapping genes were calculated using the hypergeometric distribution using the Keisan Online Calculator (http//keisan.casio.com/exec/system/1180573201, accessed on 4 August 2022). Supplementary Materials: The following supporting information can be downloaded at: https: //www.mdpi.com/article/10.3390/ncrna8050062/s1, Figure S1: Mapped 3 0 and 5 0 ends of lnc-primiR-181a2/b2; Figure S2: 3 0 -end mapping and Lnc-Nr6a1 sequences; Figure S3: Coding capacity of Lnc-Nr6a1; Figure S4: Lnc-Nr6a1 human orthologue; Figure S5: Screenshot of H3K4me3, H3K27ac, ATAC-seq and RNA-seq tracks at Lnc-Nr6a1 genomic region and scatter plot of expression of miR181a2-3p and its host gene Lnc-Nr6a1 in human cancers; Figure S6: Validation by RT-qPCR of expression of genes in Lnc-Nr6a1-depleted cells; Figure S7: Cell cycle analysis and cell proliferation of Lnc-Nr6a1-depleted cells; Figure S8: Cell cycle analysis and cell proliferation of lnc-Nr6a1-1overexpressing and lnc-Nr6a1-2-overexpressing cells; Figure S9: Proliferation and cell adhesion of cells over-expressing Lnc-Nr6a1 gene; Figure S10: Lamin A/C-associated domains; Figure S11: Human Lnc-Nr6a1 expression in tumors and normal tissues; Table S1: Transcriptomic analysis of Lnc-Nr6a1-depleted cells; Table S2: Gene Ontology enrichment analysis of downregulated genes in Lnc-Nr6a1-depleted cells; Table S3: Transcriptomic profile of NMuMG cells treated with TGFβ ; Table S4: Transcriptomic profile of Lnc-Nr6a1-depleted NMuMG cells treated with TGFβ ; Table S5: The lnc-Nr6a1-1 protein interactome; Table S6: Genes in LADS lost and LADS gain in Lnc-Nr6a1depleted cells; Table S7: Peptide-spectrum match counting for enolase1 coimmunoprecipitation assay; Non-Coding RNA 2022,8, 62 25 of 27 Table S8: Primers and oligonucleotides related to experimental procedures; Video S1: Wound-healing assay; Video S2: Wound-healing assay. Author Contributions: Conceptualization, S.P.-G. and J.A.P.-T.; methodology, S.P.-G., B.T., E.C., J.V. and J.A.P.-T.; software, J.A.G.-M. and J.C.R.; formal analysis, S.P.-G., J.C.R., J.A.G.-M. and J.A.P.-T.; investigation, S.P.-G., B.T. and J.A.P.-T.; writing—original draft preparation, J.A.P.-T.; visualization, S.P.-G. and J.A.P.-T. supervision, J.A.P.-T.; project administration, J.A.P.-T.; funding acquisition, J.A.P.-T. All authors have read and agreed to the published version of the manuscript. Funding: This research was funded by Ministerio de Economía y Competitividad, grant number SAF2017-861892-P and PID2020-119732RB-100 to J.A.P.-T. and PGC2018-097019-B-100 and PID2021122348NB-100 to J.V., and by la Caixa Banking Foundation, project codes HR17-00247 and HR22-00253 to J.V. Institutional Review Board Statement: Not applicable. Informed Consent Statement: Not applicable. Data Availability Statement: NGS data have been deposited to Gene Expression Omnibus (GEO) under the accession number GSE207917. GSE207915 and GSE207916 correspond to accession numbers of ChIP-seq data and RNA-seq data, respectively. (These data can be accessed through the link https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE207917 (accessed on 4 August 2022) with the Reviewers Token: ojkxyiayxbudbsz). Acknowledgments: We wish to thank Abelardo López-Rivas, Mary K. Collins and Maite Huarte for providing valuable reagents and Cristina Rodríguez-Mateo for critical reading of the manuscript. Conflicts of Interest: The authors declare no conflict of interest. References 1. Kalluri, R.; Weinberg, R.A. The basics of epithelial-mesenchymal transition. J. Clin. Investig. 2009 ,119, 1420–1428. [CrossRef] [PubMed] 2. Xu, J.; Lamouille, S.; Derynck, R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009 ,19, 156–172. [CrossRef] [PubMed] 3. Nieto, M.A.; Huang, R.Y.; Jackson, R.A.; Thiery, J.P. Emt: 2016. Cell 2016,166, 21–45. [CrossRef] 4. Shapiro, I.M.; Cheng, A.W.; Flytzanis, N.C.; Balsamo, M.; Condeelis, J.S.; Oktay, M.H.; Burge, C.B.; Gertler, F.B. An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype. PLoS Genet. 2011 ,7, e1002218. [CrossRef] [PubMed] 5. Rodriguez-Mateo, C.; Torres, B.; Gutierrez, G.; Pintor-Toro, J.A. Downregulation of Lnc-Spry1 mediates TGF-beta-induced epithelial-mesenchymal transition by transcriptional and posttranscriptional regulatory mechanisms. Cell Death Differ. 2017,24, 785–797. [CrossRef] 6. Zaravinos, A. The Regulatory Role of MicroRNAs in EMT and Cancer. J. Oncol. 2015,2015, 865816. [CrossRef] 7. Uszczynska-Ratajczak, B.; Lagarde, J.; Frankish, A.; Guigo, R.; Johnson, R. Towards a complete map of the human long non-coding RNA transcriptome. Nat. Rev. Genet. 2018,19, 535–548. [CrossRef] 8. Statello, L.; Guo, C.J.; Chen, L.L.; Huarte, M. Gene regulation by long non-coding RNAs and its biological functions. Nat. Rev. Mol. Cell Biol. 2021,22, 96–118. [CrossRef] 9. Quinn, J.J.; Chang, H.Y. Unique features of long non-coding RNA biogenesis and function. Nat. Rev. Genet. 2016 ,17, 47–62. [CrossRef] 10. Keniry, A.; Oxley, D.; Monnier, P.; Kyba, M.; Dandolo, L.; Smits, G.; Reik, W. The H19 lincRNA is a developmental reservoir of miR-675 that suppresses growth and Igf1r. Nat. Cell Biol. 2012,14, 659–665. [CrossRef] 11. Lu, Y.; Zhao, X.; Liu, Q.; Li, C.; Graves-Deal, R.; Cao, Z.; Singh, B.; Franklin, J.L.; Wang, J.; Hu, H.; et al. lncRNA MIR100HGderived miR-100 and miR-125b mediate cetuximab resistance via Wnt/beta-catenin signaling. Nat. Med. 2017 ,23, 1331–1341. [CrossRef] [PubMed] 12. Tseng, Y.Y.; Moriarity, B.S.; Gong, W.; Akiyama, R.; Tiwari, A.; Kawakami, H.; Ronning, P.; Reuland, B.; Guenther, K.; Beadnell, T.C.; et al. PVT1 dependence in cancer with MYC copy-number increase. Nature 2014,512, 82–86. [CrossRef] [PubMed] 13. Kong, L.; Zhang, Y.; Ye, Z.Q.; Liu, X.Q.; Zhao, S.Q.; Wei, L.; Gao, G. CPC: Assess the protein-coding potential of transcripts using sequence features and support vector machine. Nucleic Acids Res. 2007,35, W345–W349. [CrossRef] 14. Wang, L.; Park, H.J.; Dasari, S.; Wang, S.; Kocher, J.P.; Li, W. CPAT: Coding-Potential Assessment Tool using an alignment-free logistic regression model. Nucleic Acids Res. 2013,41, e74. [CrossRef] [PubMed] 15. Yu, L.; Hebert, M.C.; Zhang, Y.E. TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J. 2002,21, 3749–3759. [CrossRef]